Hypertension
Conditions
Interventions
The hypertensive patients under amlodipine administration are intended for enrolement of this study. The patients are assigned to Group A (amlodipine).
The hypertensive patients under amlodipine admin
Sponsors
Molecular Cardiovascular Medicine, Nagoya University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The hypertensive patients under amlodipine administration for more than 3 months are intended for enrolement of this study. 1. Age; over 20 years old 2. Clinical data AST<100IU/L ALT<100IU/L Cre<1.5mg/dl 3. Informed consent is needed.
Exclusion criteria
Exclusion criteria: 1. The patients under calcium blocker other than amlodipine. 2. Uncontroled hypertensive patients with over 140mmHg (systolic) or 90mmHg (diastolic). 3. The patients with bilateral renal artery stenosis or the patients of 1 kidney with renal artery stenosis. 4. The patients with malignancy needed chemotherapy. 5. The patients who has experienced serious side effects for angiotensin receptor type 1 blocker or calcium blocker.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The plasma levels of adipocytokines (Adiponectin, Omentin, Aedipolin, C1q/TNF-related protein (CTRP)-1,6,9, FAM132B, FSTL-1, C1ORF54, Neuron-derived neurotrophic factor (NDNF)) after 4 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure Clinical data | — |
Countries
Japan
Contacts
Public ContactKoji Ohashi
Nagoya University School of Medicine Molecular Cardiovascular Medicine
Outcome results
None listed